e-learning
resources
Barcelona 2013
Wednesday, 11.09.2013
Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The “COLD-PCR-approach” for early and cost-effective detection of tyrosine kinase inhibitor resistance
F. Mairinger, C. Vollbrecht, A. Streubel, A. Roth, R. Walter, T. Mairinger (Essen, Cologne, Berlin, Germany)
Source:
Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Session:
Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Session type:
Poster Discussion
Number:
5094
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Mairinger, C. Vollbrecht, A. Streubel, A. Roth, R. Walter, T. Mairinger (Essen, Cologne, Berlin, Germany). The “COLD-PCR-approach” for early and cost-effective detection of tyrosine kinase inhibitor resistance. Eur Respir J 2013; 42: Suppl. 57, 5094
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Optimization of cfDNA routine use for NSCLC genomic alteration analysis
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
CK2 enzyme affinity against c-myc
424-434
substrate in human lung cancer tissue
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
Proapoptotic effects of PAI-1 protein on lung and prostate cancer cells
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP)
Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy
Year: 2013
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Automated target-FISH lung cancer detection (LCD) test of induced sputum
Source: International Congress 2015 – Developments in lung cancer diagnosis
Year: 2015
RT-PCR and IHC as the alternative methods for detection of ALK aberrations in NSCLC samples - The feasibility study
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
The diagnostic puzzle of
ALK
rearrangement in lung cancer. A novel intron related abnormality
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
EGFR mutation diagnostic program for NSCLC patients in Poland between 2011-2014
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
MET genetic lesions in NSCLC are functional markers of early hematogenous spreading and radioresistance
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Investigate which PKC isoform play an important role in human lung cancer cells against TRAIL-induced apoptosis
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Expression and clinical significance of S100 calcium binding protein A2 in lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept